Weekly Roundup: May 31- June 4

POLL: Do you think benzene contamination in sunscreens is more widespread than we think?

Spironolactone Underused, Isotretinoin Overmonitored

Dermatologists are divided over concerns of spironolactone being underused in women and patients taking isotretinoin being overmonitored.

Food Supplement Demonstrates Positive Results in Psoriasis Therapy

AxisBiotix-Ps food supplement shows positive results in a recent consumer study evaluating its efficacy for psoriasis treatment.

New Alternative for Skin Aesthetics

The SaltFacial achieves promising results in treating multiple skin conditions.

FDA Approves Secukinumab for Pediatric Plaque Psoriasis

Secukinumab (Cosentyx, Novartis) has received FDA approval for the treatment of children and adolescents with moderate to severe plaque psoriasis.

What’s Trending in Skin Care? June 2021

Each month, Dermatology Times® features a roundup of products trending in skin care. Click here to find out what products are trending for the month of June.

Cosibelimab Being Evaluated for Metastatic cSCC

The anti–PD-L1, fully human monoclonal antibody cosibelimab will be examined in a cohort of patients with metastatic cutaneous squamous cell carcinoma (cSCC) as part of an ongoing phase 1 study.

Trichoscopy Advances Hair and Scalp Disease Diagnoses

Trichoscopy, which is based on dermoscopy, can be a valuable tool for diagnosing conditions that cause hair loss and inflammatory scalp disease.

Treatments Updates for BCC, SCC

BCC, SCC treatments take advantage of refinements in established techniques and new technology.

Dupilumab Linked to Increased Ocular Disease Prevalence in AD Patients

There may be an association between atopic dermatitis severity and diagnosis of ocular disease, such as conjunctivitis.

Caring for Gender and Sexual Minority Patients

Klint Peebles, MD, FAAD, co-chair of the AAD LGBTQ/GSM Expert Resource Group, discusses how to provide the best care for your gender and sexual minority patients.

Tapinarof Cream Submitted for Approval for Treatment of Plaque Psoriasis

Dermavant has submitted a New Drug Application (NDA) to the FDA seeking approval for its novel topical for the treatment of mild, moderate, and severe plaque psoriasis in adult patients.

FDA to Initiate Pre-Approval Inspection of DAXI Manufacturing Facility

Revance provides an update on the approval process for its injectable daxibotulinumtoxinA (DAXI) for the treatment of glabellar lines.